CD47 Target Evaluation Report: Biology, Validation, Competition, IP, and R&D Strategy
CD47 Target Evaluation Report: Biology, Validation, Competition, IP, and R&D Strategy
This CD47 target evaluation report is generated based on structured data from PatSnap Target & Disease MCP and PatSnap Clinical Trials MCP. It turns target biology, disease context, clinical validation, competitive intensity, and IP strategy into a repeatable target evaluation workflow for life sciences AI agents.
Explore PatSnap Life Sciences MCP Servers
Target CD47 UniProt Q08722 | Target-linked drugs 228 156 active development drugs | AML trials 33 CD47 + AML MCP query | Released results 34 Clinical result query |
Executive View
CD47 is an immuno-oncology target built around the “don’t eat me” macrophage checkpoint axis. In AML, it has meaningful clinical activity signals and strong combination logic with azacitidine and venetoclax, but development risk is material because hematologic toxicity, red-blood-cell biology, and study reproducibility define the bar for new entrants.
- Biology: Target & Disease MCP identifies CD47 as an adhesive immunoregulatory protein and receptor for SIRPA, involved in cell-cell interaction and immune modulation.
- Disease context: AML is a clonal expansion of myeloid blasts in bone marrow, blood, and other tissues, with 1,006 development drugs in the disease record.
- Validation: Clinical Trials MCP returns 33 CD47 + Acute Myeloid Leukemia trials and 34 released result records.
- Strategy: Prioritize macrophage-checkpoint combination logic, anemia/hemagglutination mitigation, AML genotype segmentation, and venetoclax/azacitidine positioning.
Scorecard
Biology confidence: High immune rationale
Clinical validation: Active but mixed-risk
Competitive pressure: High
White-space potential: Combination-led
Biology and Disease Rationale
Target & Disease MCP returns CD47 with UniProt Q08722, 228 target-linked drugs, and 156 active development drugs. The target profile describes CD47 as an adhesive protein involved in signal transduction, inflammation, apoptosis, angiogenesis, cellular self-renewal, and immunoregulation. Its interaction with SIRPA provides a mechanistic basis for macrophage-checkpoint targeting.
For acute myeloid leukemia, Target & Disease MCP describes clonal expansion of myeloid blasts in bone marrow, blood, and other tissues. The disease record shows 1,006 development drugs and 1,253 roll-up development drugs, making differentiation and patient selection central to CD47 program design.
Explore PatSnap Life Sciences MCP Servers for AI agents
Selected Trial and Result Evidence
| AK117 + azacitidine + venetoclax Clinical Trials MCP returned a not-yet-recruiting Phase 1/2 study in AML, highlighting the common CD47 plus hypomethylating agent/venetoclax strategy. |
| AUR103 calcium in relapsed advanced malignancies Open-to-recruitment Phase 1/2 study, showing continued early development of CD47-related approaches. |
| AK117 randomized Phase 2 result Clinical trial result query returned a positive Phase 2 record for AK117 versus placebo in combination with venetoclax and azacitidine in previously untreated AML patients ineligible for intensive chemotherapy. |
| Magrolimab combinations Released positive Phase 2 multi-arm result record for magrolimab combinations in AML. |
IP and R&D Recommendation
CD47 IP review should map anti-CD47 and SIRPA-axis binders, Fc engineering, priming-dose schedules, anemia mitigation claims, azacitidine/venetoclax combinations, AML genotype use claims, and macrophage-checkpoint combination portfolios.
Recommendation
CD47 remains scientifically attractive, but new AML programs must directly address safety and reproducibility. The clearest thesis is a differentiated CD47/SIRPA construct with better hematologic tolerability and strong combination evidence in AML subgroups.
Start building target evaluation agents with PatSnap Life Sciences MCP Servers
Data note: Target biology, disease profile, clinical trial counts, trial examples, and result evidence were generated from PatSnap Target & Disease MCP and PatSnap Clinical Trials MCP queries performed on July 9, 2026.
